Mark Gitau, MD
Medical Oncology · Fargo, NDNPI 1225073661
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,147 of the $1,427 with a category attached, or 80.4%. Merck accounts for 92.0% of it on its own, with 3 other manufacturers making up the rest. 2024 is the largest year on record at $1,331, more than ten times the $73 reported in 2019.
Across 11 payments — averaging $129.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Blue Earth Diagnostics$73
- Tempus AI, Inc$29
- Gilead$12
Across 7 payments — averaging $30,863 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$216K
What the payments were for
- Travel & lodging$1,14780%
- Food & beverage$26819%
- Education$121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $1,313 |
| Blue Earth Diagnostics | 1 | $73 |
| Tempus AI, Inc | 1 | $29 |
| Gilead | 1 | $12 |
How this compares
Too few medical oncology providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 14 | $200,473 |
| TagrissoOsimertinib Mesylate | 12 | $197,242 |
| ImbruvicaIbrutinib | 12 | $195,611 |
| CalquenceAcalabrutinib Maleate | 12 | $172,174 |
| EliquisApixaban | 21 | $13,655 |
| Anastrozole | 149 | $3,560 |
| Exemestane | 11 | $2,904 |
| Imatinib Mesylate | 13 | $2,386 |
| Letrozole | 85 | $1,807 |
| Prochlorperazine Maleate | 27 | $528 |
| Tamoxifen Citrate | 14 | $338 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $277 |
| Hydroxyurea | 17 | $216 |
| Gabapentin | 22 | $202 |
| Prednisone | 23 | $143 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Fargo
- Bassim KobrossyFargo$439
- John TateFargo$87
- Preston SteenFargo$44
- Denise SnowFargo$37
- Janet MacheledtFargo$12
- Chad PedersenWatford City$74K
- Todor DentchevGrand Forks$11K
- Patanit WatanaboonyakhetMinot$194
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.